Financials
Financial year 2025
EsoBiotec from Mont-Saint-Guibert, company number BE0756885159, closed financial year 2025 with a result of € 7.7 million after tax. For that financial year EsoBiotec recorded a gross margin of € 26.8 million and equity of € 12.4 million. Compared with financial year 2024, the result moved from € -6.9 million to € 7.7 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.
€ 12.4 million
▲ € 10.9 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 7.7 million
▲ still € 6.9 million loss in 2024
Profit after tax over the fiscal year.
€ 113,183
▼ 91% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -3 million.
People and assets in 2025
9.4
▼ 1.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.6 million
▲ 157% vs 2024
€ 278,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 398,138
▼ 63% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 3.7 million
▲ € 3.5 million vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 2,176,305 | € 483,654 | € -761,751 | € 26,772,082 | ▲ € 27.5 million |
| Profit after taxes | € -1,002,978 | € -2,673,233 | € -6,875,362 | € 7,732,667 | ▲ € 14.6 million |
| Equity | € 5,051,745 | € 2,378,511 | € 1,503,109 | € 12,414,984 | ▲ € 10.9 million |
| Total debts | € 2,235,184 | € 4,132,355 | € 2,794,550 | € 4,066,415 | ▲ 46% |
| Cash | € 4,131,494 | € 1,401,551 | € 1,305,728 | € 113,183 | ▼ 91% |
| Retained profit | € -1,201,296 | € -3,874,529 | € -10,749,891 | € -3,017,225 | ▲ € 7.7 million |
| Bank debt | € 792,121 | € 2,709,479 | € 1,137,143 | € 0 | ▼ 100% |
| Balance sheet total | € 7,286,928 | € 6,510,867 | € 4,297,659 | € 16,481,399 | ▲ 283% |
| Employees (FTE) | - | - | 10.6 | 9.4 | ▼ 1.2 |
Key figures of EsoBiotec, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to EsoBiotec?
What happened at EsoBiotec in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- CARSTEN LINNEMANN stepped down as director. NBB
- ANGELA THOMPSON stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 7.7 million. Source: NBB ↗
- JEAN-PIERRE LATERE DWAN'ISA stepped down as director. NBB
- CARSTEN LINNEMANN became a director. NBB
- ANGELA THOMPSON became a director. NBB
- JEAN-PIERRE LATERE DWAN'ISA became a director. NBB
- New establishment in Mont-Saint-Guibert. KBO
In short
From € 1 million loss in 2022 to € 7.7 million profit in 2025.
Paid € 4.1 million in corporate taxes since 2022.
Best year ever: 2025, with € 7.7 million profit.
On average € 2.8 million of value added per employee in 2025.
A new publication or filing at EsoBiotec? We notify you, reason included.
Follow EsoBiotecDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of UCB Ventures, Wallonie Entreprendre comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
EsoBiotecThe shares are held by Neogene Therapeutics (100%), UCB Ventures (18.8%) and Wallonie Entreprendre (11.8%).
Directors
According to the 2025 annual accounts
CARSTEN LINNEMANN
Director
since 2025 · until 2031
since 2024 · until 2026
ANGELA THOMPSON
Director
since 2025 · until 2031
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue André Dumont 5
1435 Mont-Saint-Guibert
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0756.885.159
- VAT number
- BE 0756.885.159
- Registered office
- Rue André Dumont 5, 1435 Mont-Saint-Guibert
- Names & denominations
- EsoBiotec
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 October 2020
- Peppol
- Active · Active since 30 Dec 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied